Benmelstobart clinical trials
Also written TQB2450.
How each study uses benmelstobart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the benmelstobart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
80 studies that test it; most in 2026 (14)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 8 |
| 2020 | 10 |
| 2021 | 7 |
| 2022 | 7 |
| 2023 | 9 |
| 2024 | 12 |
| 2025 | 12 |
| 2026 | 14 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 32 · Other 48
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (30) · Sun Yat-sen University (4) · Henan Cancer Hospital (3) · The First Affiliated Hospital of Zhengzhou University (3) · Tianjin Medical University Cancer Institute and Hospital (3) · Fudan University (3) · Shanghai Pulmonary Hospital, Shanghai, China (3) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (2)
Often tested with
Tested in the same studies.
Anlotinib (44) · Catequentinib hydrochloride (11) · Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 (2) · Vilzemetkib (1) · TLR7 Agonist JNJ-64794964 (1) · Tucidinostat (1) · Partial Nephrectomy (1) · Nimotuzumab (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 14, 1 in phase 3
Studies that test benmelstobart, phase 3 first.
- Jun 2027Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell CarcinomaPhase 3 · Sun Yat-sen University
- Nov 2026Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma PatientsPhase 2 · Jiangxi Provincial Cancer Hospital
- Dec 2026Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)Phase 2 · Sun Yat-sen University
- Dec 2026A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NECPhase 2 · Tianjin Medical University Cancer Institute and Hospital
- Dec 2026Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II StudyPhase 2 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Apr 2027Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)Phase 2 · First Affiliated Hospital of Zhejiang University
- Apr 2027Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung CancerPhase 4 · Peking Union Medical College Hospital
- May 2027Anlotinib Combined With Benmelstobart for Advanced PheochromocytomaPhase 2 · Sun Yat-sen University
- Jun 2027Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple MetastasesPhase 2 · Xinqiao Hospital of Chongqing
- Jun 2027Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung AdenocarcinomaPhase 2 · Shanghai Pulmonary Hospital, Shanghai, China
Studies
Open first, then newest update. How each study uses benmelstobart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 80
- Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part SarcomaRecruitingPhase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07548177Written as Benmelstobart injection combined with Anlotinib hydrochloride capsule
- Chidamide Combined With Benmelstobart, Nab-paclitaxel, and SBRT as Second-Line Treatment for Advanced BTCNot yet recruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07890506Written as chidamide+benmelstobart+nab-paclitaxel+SBRT
- An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung CancerNot yet recruitingNot applicableZhejiang Cancer HospitalNCT07849712Written as Benmelstobart Combined With Anlotinib
- Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II StudyRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07806292Written as anlotinib combined with benmelstobart and HAIC
- A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for Elderly Patients With Small-cell Lung Cancer or Those Who Are Intolerant to Intensive ChemotherapyNot yet recruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07728955Written as benmelstobart in combination with anlotinib and etoposide
- Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed by Concurrent Chemoradiotherapy and Benmelstobart Maintenance Versus Concurrent Chemoradiotherapy Followed by Benmelstobart Maintenance in Patients With Unresectable Stage III NSCLCNot yet recruitingPhase 2The Third Xiangya Hospital of Central South UniversityNCT07643350Written as Benmelstobart
- Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial NephrectomyNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07627464Written as Anlotinib hydrochloride + Benmelstobart + Partial nephrectomy
- TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd ECRecruitingPhase 2Fudan UniversityNCT06914297Written as TQB2450 injection + oral progestin
- Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell CarcinomaNot yet recruitingPhase 2RenJi HospitalNCT07602101Written as TQB2450 + Anlotinib
- Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell CarcinomaNot yet recruitingPhase 2/3Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityNCT07535567Written as Nimotuzumab, Benmelstobart
- A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung CancerNot yet recruitingPhase 2Yayi HeNCT07538271Written as benmelstobart
- Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung CancerNot yet recruitingPhase 2Yayi HeNCT07538258Written as Benmelstobart
- Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted TherapyNot yet recruitingPhase 2Nanfang Hospital, Southern Medical UniversityNCT07537777Written as Benmelstobart
- A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NECNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07510594Written as Benmelstobart+ Anlotinib+ Platinum + Etoposide
- A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingPhase 3The First Affiliated Hospital of Zhengzhou UniversityNCT07446335Written as anlotinib combined with benmelstobart
- Anlotinib and Benmelstobart in DTCNot yet recruitingPhase 2Fudan UniversityNCT07193186Written as Anlotinib and Benmelstobart
- Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer PatientsRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT06662006Written as nal-IRI,5-fu,LV, benmelstobart, anlotinib
- Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLCNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07294261Written as Garsorasib, Benmelstobart, Anlotinib
- A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene AbnormalityRecruitingPhase 2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06496490Written as TQB2102 for injection combined with Benmelstobart injection
- Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)RecruitingPhase 2First Affiliated Hospital of Zhejiang UniversityNCT06874933Written as Neoadjuvant Chemotherapy in Combination with Anlotinib and Benmelstobart
See all 80 studies that test benmelstobart →
Given beside what is tested · 7 — benmelstobart is usual care or a partner of the new treatment
- Risk-Adapted Anlotinib and PD-L1 for Locoregionally Advanced Nasopharyngeal CarcinomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07904819Written as Benmelstobart
- A LM-302 Combination With Other Anti-Tumor Therapies Phase ll StudyRecruitingPhase 2LaNova Medicines Zhejiang Co., Ltd.NCT05934331Written as Benmelstobart
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499Written as Benmelstobart
- Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal CarcinomaNot yet recruitingPhase 3Sun Yat-sen UniversityNCT07385079Written as Benmelstobart
- An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid TumorsRecruitingPhase 1/2Beijing Tide Pharmaceutical Co., LtdNCT07371663Written as benmelstobart Injection
- Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung CancerNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07172412Written as Tislelizumab/Atezolizumab/ Durvalumab/Benmelstobart/Toripalimab/Serplulimab
- Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.TerminatedPhase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05481645Written as TQB2450 injection
As the comparator · 1 — what is tested is compared with benmelstobart
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered2
Codes
What other systems call benmelstobart · ClinicalTrials.gg INT016056
- UNII (FDA) B25CF42QKPBENMELSTOBARTOne source FDA
- NCI Thesaurus C156692BenmelstobartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | B25CF42QKP | BENMELSTOBART | One source FDA |
| NCI Thesaurus | C156692 | Benmelstobart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.